Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1537-2995|55|2|275-283

ISSN： 0041-1132

Source： TRANSFUSION, Vol.55, Iss.2, 2015-02, pp. : 275-283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study

By  

Acta Haematologica, Vol. 135, Iss. 1, 2015-0 ,pp. : 29-36

Karger

Access to resources Recommend Favorite

Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation

By  

TRANSFUSION, Vol. 55, Iss. 8, 2015-08 ,pp. : 1993-2000

John Wiley & Sons Inc

Access to resources Recommend Favorite

Poor peripheral blood stem cell mobilization affects long‐term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 33, Iss. 1, 2018-02 ,pp. : 29-37

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of myeloma in younger patients

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 1, 2015-01 ,pp. : 94-105

John Wiley & Sons Inc

Access to resources Recommend Favorite

Myeloma therapy in older patients

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 3, 2015-03 ,pp. : 335-343

John Wiley & Sons Inc

Access to resources Recommend Favorite